AKA. I. Kramarenko

A. I. Kramarenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. I. Kramarenko has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The first experience of two-stage transcatheter implantation of bioprostheses in mitral and tricuspid valve (Valve-in-Valve) prostheses in a high-risk surgical patient

    by L. S. Kokov, I. G. Eliseev, M. V. Parkhomenko, N. M. Bikbova, A. I. Kramarenko, M. F. Budaeva, A. I. Kovalev, D. A. Fedyaev

    Introduction. Structural degeneration of biological prosthetic heart valves is an inevitable complication in the long term, requiring repeated surgery. Repeated open surgery is associated with a high risk in comorbid patients. Valve-in-Valve (ViV) transcatheter technology has become a minimally invasive alternative. Objective. To demonstrate the effectiveness and safety of a two-stage ViV strategy on tricuspid and mitral valves. Material and methods. A clinical case of a patient born in 1947 with mitral valve (MC) and tricuspid valve (TC) bioprostheses 7 years after the initial open prosthetics is presented. The calculated risk of EuroSCORE II was 21.8%. A two-stage strategy was applied: on 09.29.2025, transcatheter implantation of the MyVal 30.5 mm bioprosthesis was performed in the tricuspid valve position, and on 10.10.2025, MyVal 27.5 mm was performed in the mitral valve position. Results. The postoperative period was uneventful. Control echocardiography showed a significant improvement in hemodynamic parameters: the average gradient on TC decreased from 6.0-7.2 to 3.1 mmHg, regurgitation decreased from 2 to 0-1 art. On MC, the average gradient decreased from 9.0-10.5 mmHg to 6.7 mmHg, regurgitation was minimal. The patient's condition was satisfactory upon discharge, FC regressed from III-IV to II. Conclusion. Two-stage transcatheter valve implantation using valve-to-valve technology is a highly effective and safe method of treating bioprosthesis dysfunction in high-risk surgical patients, which avoids repeated sternotomy and reduces rehabilitation time.

  • Open Access

    Spontaneous soft tissue hematomas in patients with severe COVID‑19 infection

    by E. S. Vladimirova, F. A. Chernousov, E. V. Klychnikova, I. E. Popova, A. I. Kramarenko, O. A. Alekseechkina, K. A. Popugaev, P. A. Yartsev, R. Sh. Bayramov

    Спонтанные гематомы мягких тканей у пациентов с тяжелой инфекцией COVID‑19


  • Open Access

    Features of Diagnosis and Treatment of Spontaneous Extraorganic Hematomas of the Soft Tissues of the Neck and Chest

    by E. S. Vladimirova, E. A. Tarabrin, I. E. Popova, K. A. Popugayev, A. I. Kramarenko

    The possibilities of computed tomography in the diagnosis of spontaneous hematomas (sh) of the soft tissues of the neck and chest and the features of their treatment are shown. Computed tomography with intravenous bolus contrast enhancement is the main method for diagnosing sh, which allows you to specify its exact localization, distribution, determine the structure and volume of the hematoma, the contrast agent exiting the contours of the vessel, and, taking into account the data obtained and the clinic, determines the tactics of treatment.Stable sh does not require surgical treatment. In the case of a large volume of chest hematoma, compression syndrome, hemothorax, drainage is indicated. Unstable sh dictate the need for angiography and, if necessary, endovascular embolization.


  • Open Access

    Course and Outcomes of Acute Coronary Syndrome in the Presence of New Coronavirus Infection COVID-19

    by L. S. Kokov, S. S. Petrikov, M. M. Pisankina, E. A. Dashevsky, K. A. Popugayev, M. V. Parkhomenko, И. М. Кузьмина, I. S. Babayan, K. I. Vorontsova, L. T. Khamidova, et al.

    We analyzed the clinical condition of patients with COVID-19 of varying severity, changes in instrumental and laboratory parameters, and assessed the impact of the severity of the course of a new coronavirus infection on the outcomes of acute coronary syndrome.AIM OF STUDYTo study the mutual influence of acute coronary syndrome and the new coronavirus infection COVID-19 on the nature of the course and outcomes of the disease.Materia l and methodsIn March 21, 2020 – May 31, 2021, 3 625 patients were treated for COVID-19, including 131 patients with acute coronary syndrome due to COVID-19 disease. All patients underwent a number of studies: computed tomography of the chest, electrocardiography, echocardiography, monitoring of biomarkers of myocardial damage, diagnostic coronary angiography and, if necessary, intracoronary therapeutic intervention.ResultsData on the distribution of patients with COVID-19 according to the presence or absence of ST segment elevation on the electrocardiogram and the degree of lung tissue damage, as well as information on mortality in these groups, are presented. The role of troponin I in the assessment of myocardial ischemia was analyzed. The direct dependence of its level on the volume of lung damage was found. The inverse relationship was shown between the degree of damage to the lung tissue and the indices of oxygen saturation in the blood. A poor prognostic value of low left ventricular ejection fraction in patients with COVID-19 disease has been described.ConclusionsThe development of acute coronary syndrome in the course of COVID-19 significantly worsens the prognosis of the disease, which requires the development of algorithms for providing medical care to patients in this category, as well as maximum vigilance in their treatment.